Inloggen

Login
 
Wachtwoord vergeten?

Amerikaanse aandelen« Terug naar discussie overzicht

Viking Therapeutics (VKTX) succes met NASH..?

73 Posts
Pagina: «« 1 2 3 4 »» | Laatste | Omlaag ↓
  1. forum rang 5 Hulskof 4 mei 2019 15:02
    Bedankt voor de link, WH.

    'One very large potential catalyst for the stock could be the announcement of a partnership for VK2809, although we admit it is difficult to handicap the possibility for one at this point. Fortunately, Viking is in very strong financial shape and is able to move forward with development of VK2809 on its own, but with the stellar efficacy and safety of the drug we believe it is a very attractive partnership opportunity. Our valuation remains $24.'

    Bemoedigende woorden. Ik zie die koers nog liever vandaag dan morgen! :-)

    Had je trouwens nog bijgekocht? Bodem lijkt weer even gezet.
  2. [verwijderd] 6 mei 2019 09:27
    quote:

    Hulskof schreef op 5 mei 2019 15:51:


    Ja, heb er nog altijd een paar honderd. Lange termijn, zeg ik altijd tegen m'n vrouw, maar ik ben ongeduldig. ;-)
    Ik hoop dat ze snel een goeie partner vinden. Dat zou de koers denk ik een flinke boost geven. En die shorters moeten eruit.

    Wellicht je vrouw ook.
  3. forum rang 4 Wil Helmus 15 mei 2019 15:21
    Viking Therapeutics risk/reward symmetry skewed to upside, says William Blair William Blair analyst Andy Hsieh reiterates an Outperform rating on Viking Therapeutics (VKTX) after hosting investor meetings the company's CEO Brian Lian. The analyst continues to view Viking's risk/reward symmetry as skewed to the upside, especially with the recent sector volatility and the "continued significant valuation gap" with competitor Madrigal Pharmaceuticals (MDGL). Viking is on track to file an investigational new drug application later this year to the FDA's Division of Gastroenterology and Inborn Errors Products, which would enable the company to initiate the Phase II biopsy-confirmed nonalcoholic steatohepatitis study, Hsieh tells investors in a research note.

    Read more at: 
    thefly.com/landingPageNews.php?id=290...
  4. forum rang 5 Hulskof 18 mei 2019 23:12
    Interessant. Zowel goed als slecht nieuws dus. Je hoeft beslist niet de eerste te zijn (Viking heeft een paar jaar achterstand), maar de diagnostiek is waarschijnlijk het grootste probleem, zoals ook onderstaand artikel weergeeft.

    www.biopharmadive.com/news/nash-liver...

    Het lijkt erop dat het definitief een langetermijninvestering gaat worden, waarbij het gouden ei eerst gelegd wordt door de firma die met de beste diagnostische test komt. GenFit werkt aan een bloedtest. Misschien kunnen we beter eerst daar ons geld instoppen...
  5. forum rang 4 Wil Helmus 31 mei 2019 20:51
    3 Stocks to Buy and Hold for the Next 50 Years

    George Budwell (Viking Therapeutics): Investing in clinical-stage biotech stocks requires patience. As a point of fact, most drugs take upwards of a decade to complete the rigorous clinical trials process, and then it can take another two to three years for a drug to begin to carve out a profitable niche following approval. Small-cap, pre-revenue biotech Viking Therapeutics is no exception to this trend. But the pay-off for early-bird investors in this promising developmental biotech could be enormous. 

    Viking's investing thesis centers on the company's experimental non-alcoholic steatohepatitis (NASH) candidate VK2809. VK2809 has already posted stellar mid-stage results in patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company thus plans to evaluate the drug in another mid-stage trial later this year as a treatment for NASH. If this next trial pans out, Viking should be poised to launch a pivotal NASH trial by either late 2020 or early 2021. The big deal is that NASH is forecast to grow into a $35 billion a year market, and there are currently no drugs approved for this devastating liver disease. 

    Stacks of coins with investment concept words written on them

    It's never too early to plan for your future. Image source: Getty Images.

    The best part of this story is that VK2809 seems capable of becoming a backbone therapy for NASH based on its outstanding mid-stage results, although critics have been quick to point out that the drug has yet to be assessed in this particular indication directly. As an important side note, Viking is also gearing up to launch an early-stage study for VK0214 in patients with a genetic disease known as X-linked adrenoleukodystrophy, giving the company yet another major value driver in the years to come. 

    In all, Viking isn't a stock that's going to make you rich overnight, but it could be a great long-term buy-and-hold for risk-tolerant investors
73 Posts
Pagina: «« 1 2 3 4 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 659,30 0,00%
EUR/USD 1,2134 +0,20%
Germany30^ 13.968,00 +0,33%
Gold spot 1.874,23 +0,20%
LDN100-24h 6.760,68 +0,19%
NY-Nasdaq Composite 13.457,25 +1,97%

Stijgers

AALBER...
0,00%
ABN AM...
0,00%
Accell
0,00%
Accsys
0,00%
Acomo
0,00%

Dalers

AALBER...
0,00%
ABN AM...
0,00%
Accell
0,00%
Accsys
0,00%
Acomo
0,00%
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare